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Material and Methods: Thirteen (13) institutions from the 
RCN study group among Europe and United States enrolled 
206 adult medulloblastoma patients who underwent 
postoperative RT between 1976 and 2014. All hospitals 
received their respective Institutional Review Board 
approval, and extracted data were sent to one investigator 
(B.A.) for data analyses. Log-rank univariate and Cox-
modeled multivariate analyses were performed. 
 
Results: There were 118 men and 88 women, and median age 
was 29 (range, 16-67). The median follow-up was 31 months. 
Tumor resection was performed in all patients, and surgery 
was complete in 140 (68%) of the patients. For those patients 
with reported residual volume, 83 (66%) achieved <1.5 cm2 
after resection. Histological subtype was classic (61%) 
predominantly. Postoperative RT was given in 202 (98%) 
patients, and 93% of them received craniospinal irradiation 
(CSI) to a median dose of 36 Gy, with a median RT boost of 
18 Gy to the posterior fossa. Ninety-eight (48%) patients had 
chemotherapy before, after, or concomitant with RT; the 
most common chemotherapy regimens were cisplatin and 
vincristine-based. At 5 and 10 years’ marks, the overall 
survival (OS) rates were 63 and 51%; local control (LC) rates 
were 60 and 46%; and disease-free survival (DFS) rates were 
52 and 38% for all patients, respectively. On univariate 
analyses, Karnofsky performance status (KPS) ≥ 80%, time 
between surgery and RT (≤ 47 days), negative CSF, total RT 
dose ≥ 54 Gy, CSI completion, use of boost field, and 
chemotherapy were associated with better LC, DFS, and OS. 
Additionally, complete surgery, <1.5 cm2 residual volume, 
desmoplastic pathology, and age (≤ 29) were significant 
favorable prognostic factors for DFS and OS. In multivariate 
analyses, KPS ≥ 80% (P<0.001) and CSI (P=0.0002) were the 
remaining significantly favorable prognostic factors for DFS 
and OS; presence of chemotherapy (P=0.0002) and KPS ≥ 80% 
(p=0.03) correlated with better LC rates. 
 
Conclusion: We retrospectively reported the largest clinical 
series for the treatment of adult medulloblastoma and 
elucidated prognostic factors for tumor control and also 
survival outcomes. For patients with high KPS who also 
received CSI, their DFS and OS were better. The use of 
chemotherapy may associate with better local control, 
possibly due to improved radio-sensitization. This information 
should serve as the benchmark and provide the basis for 
future prospective clinical trials in further improving the 
outcome for this group of adult patients with rare 
medulloblastoma. 
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Purpose or Objective: A multicenter randomized trial 
evaluated neurological status (including neurological deaths) 
and cognitive function of patients with resected single brain 
metastasis (BM) after stereotactic radiotherapy of the tumor 
bed (SRT-TB) in comparison with adjuvant whole-brain 
radiotherapy (WBRT). This study reports a preliminary 
comparison of pattern of failure and neurological deaths in 
this trial.  
 
Material and Methods: A planned number of 60 patients was 
randomly assigned into SRT-TB (30) and WBRT (30) arms. 
Inclusion criteria were: total or subtotal resection of BM, 
single BM in the MRI before craniotomy, KPS≥70, life 
expectancy >6 months. Patients in the SRT-TB arm received 
linac-radiosurgery of 15 Gy/1 fraction, or 5 x 5Gy if large 
cavity or proximity of critical structures. WBRT consisted of 
30 Gy in 10 fractions. Evaluation at baseline (before RT), 
eight weeks after RT, and next every three months consisted 
of EORTC QLQ-C30 - BN-20, MiniMental test, KPS, neurologic 
status, and MRI of the brain. Neurological death was defined 
as every death from progression in the brain, toxicity of 
treatment of BM, and from undetermined cause. Crude rates 
of neurological deaths and relapses in the brain were 
compared according to the treatment actually received 
analysis with chi2 test. Overall survival (OS) and interval free 
from neurological death (IFFND) rates were compared with 
log-rank test. 
 
Results: In the SRT-TB arm, six patients were ineligible (new 
BM detected during RT planning [5], withdrawal of consent 
[1]), one received WBRT by error, two had rapid extracranial 
progression (one had no BM treatment, one received WBRT), 
thus finally 21 (72%) patients received the assigned treatment 
in this group. In the WBRT arm, 29 (97%) received the 
assigned treatment. With median follow-up of 12 months 
(range: 1-36) for 26 living patients, one-year OS rates 
(intention-to-treat) were 48% (95% CI: 36-60%) and 61% (95% 
CI: 43-79%) for SRT-TB and WBRT arm, respectively, p=.14. In 
the intention-to-treat analysis, one-year IFFND rates were 
59% (95% CI: 35-84%) and 74% (95% CI: 56-93%) for SRT-TB and 
WBRT arm, respectively, p=.10. In the treatment actually 
received analysis, one-year IFFND rates were 62% (95% CI: 37-
88%) and 72% (95% CI: 53-90%) for SRT-TB and WBRT arm, 
respectively, p=.26. There were 9 (41%) and 9 (30%) 
neurological deaths, in the patients receiving SRT-TB and 
WBRT, respectively, p= .10. 
Ten (45%) of 22 patients treated with SRT-TB had relapse in 
the brain including 5 (23%) relapses in the tumor bed; 9 (31%) 
of 30 patients treated with WBRT had relapse in the brain 
including 7 (24%) relapses in the tumor bed, p=.29. 
 
Conclusion: Our results showed high rate of neurological 
deaths with omission of WBRT, thus such treatment might not 
be safe. Planned analysis of the results from our study that 
will compare neurological and cognitive functions following 
two treatments will be also helpful in decision making 
process. 
 
 
 
